Small intestinal bacterial overgrowth is associated with intestinal inflammation in the irritable bowel syndrome

David, Liliana; Babin, Alexandru; Picoș, Andrei; Dumitraşcu, Dan L.

doi:10.15386/cjmed-303

Cited by 9 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…76 A recent meta-analysis showed that the incidence of SIBO in IBS patients is 36.7% (95% CI, 24.2-44.6) and it was closely associated with intestinal inflammation. 77 , 78 There are few studies focusing on the relationship between SIBO and FD. In a small sample Brazilian study, SIBO was found in 56.5% (13/23) of patients with FD but not observed in healthy controls ( P = 0.005).…”

Section: The Role Of Non-infectious Inflammation In the Pathogenesis Of Irritable Bowel Syndrome Functional Dyspepsia And Overlap Syndrommentioning

confidence: 99%

Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia

Wang

Fang

2021

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are common functional gastrointestinal disorders (FGIDs) and account for a large proportion of consulting patients. These 2 disorders overlap with each other frequently. The pathogenesis of IBS or FD is complicated and multi-factors related, in which infectious or non-infectious inflammation and local or systemic immune response play significant roles. There are few studies focusing on the mechanism of inflammation in patients with overlap syndrome of irritable bowel syndrome and functional dyspepsia (IBS-FD). This review focuses on current advances about the role of inflammation in the pathogenesis of IBS and FD and the possible mechanism of inflammation in IBS-FD.

show abstract

Section: The Role Of Non-infectious Inflammation In the Pathogenesis Of Irritable Bowel Syndrome Functional Dyspepsia And Overlap Syndrommentioning

confidence: 99%

Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia

Wang

Fang

2021

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…showed that the prevalence of SIBO in patients with IBS varies between 39% and 54%. However, these meta‐analyses were published about a decade ago, and there has been a substantial influx of good quality studies using glucose hydrogen breath test (GHBT), and lactulose hydrogen breath test (LHBT) . Also, the earlier meta‐analysis focused on breath tests only, which are non‐invasive alternatives, albeit inferior to the gold standard method of quantitative upper gut aspirate culture.…”

Section: Introductionmentioning

confidence: 99%

A meta‐analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome

Ghoshal

Nehra

Mathur

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background Enteric microbiota is increasingly being recognized as an important factor in the pathogenesis of irritable bowel syndrome (IBS). The reported prevalence of small intestinal bacterial overgrowth (SIBO) in subjects with IBS is highly variable, and there is no consensus on the role of SIBO in different subtypes of IBS, and indications and methods of testing. Methods A comprehensive literature search was performed for studies applying tests for SIBO in subjects with IBS. After applying prospectively decided exclusion criteria, the eligible papers were examined using a meta‐analysis approach for the prevalence of SIBO in subjects with IBS using different tests. The odds ratios of SIBO among subjects with IBS as compared with healthy controls using different tests were calculated. Results Of the available studies (22, 17, 5, and 3 using lactulose and glucose hydrogen breath tests [LHBT and GHBT], jejunal aspirate culture, and more than one tests, respectively) meeting the inclusion criteria, 36.7% (95% confidence interval [CI] 24.2–44.6) had a positive test for SIBO. Patients with IBS were 2.6 (95% CI 1.3–6.9) and 8.3 (95% CI 3.0–5.9) times more likely to have a positive test for SIBO as compared with healthy controls using GHBT and jejunal aspirate culture, respectively. Patients with diarrhea‐predominant IBS were more likely to have positive GHBT as compared with the other subtypes. Conclusions Patients with IBS were more likely to have SIBO as compared with healthy subjects using GHBT and jejunal aspirate culture but not using LHBT. Patients with diarrhea‐predominant IBS more often have SIBO.

show abstract

“…Raia et al studied the concentration of FC in 30 pediatric patients with cystic fibrosis; FC levels were reported to be significantly higher compared to controls (P<0.01) and significantly lower compared to 15 patients with IBD (P<0.001) [38]. Further studies have linked higher levels of FC to small intestinal bacterial overgrowth [39], food allergy, gastroesophageal reflux disease [40], hepatic encephalopathy in patients with liver cirrhosis [41], and iatrogenic causes, such as gastric bypass surgery [42].…”

Section: Role Of Fc In Other Gi Diseasesmentioning

confidence: 99%

Clinical utility of fecal calprotectin: potential applications beyond inflammatory bowel disease for the primary care physician

Mari

Baker

Mahamid

et al. 2019

aog

View full text Add to dashboard Cite

Fecal calprotectin (FC) is an inflammatory marker released mainly from gastrointestinal granulocytes measured in stool samples. FC is noninvasive, economical, simple, and acceptable for patients. Levels of FC have proven reliable for intestinal inflammation, with good clinical sensitivity, and are useful in screening and monitoring inflammatory bowel disease (IBD), as well as in the differential diagnosis between IBD and irritable bowel syndrome (IBS). Given its advantages, FC represents an attractive biomarker that could be utilized in various gastrointestinal (GI) diseases apart from IBD, and is currently being studied extensively by many research groups with significant amounts of data emerging. In this current review we aim to provide an outline of the utility of FC in distinguishing between IBS and IBD, as well as an up-to-date summary of the available clinical experience concerning FC in various common conditions of the GI tract commonly encountered by gastroenterology practitioners, such as IBS, microscopic colitis, acute gastroenteritis, Clostridium difficile infection, colorectal cancer, diverticular disease, coeliac disease, and other GI conditions.

show abstract

Small intestinal bacterial overgrowth is associated with intestinal inflammation in the irritable bowel syndrome

Cited by 9 publications

References 15 publications

Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia

Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia

A meta‐analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome

Clinical utility of fecal calprotectin: potential applications beyond inflammatory bowel disease for the primary care physician

Contact Info

Product

Resources

About